US2014154243A1PendingUtilityA1

Specific binding agents to hepatocyte growth factor

48
Assignee: AMGEN FREMONT INCPriority: Jul 18, 2003Filed: Nov 21, 2013Published: Jun 5, 2014
Est. expiryJul 18, 2023(expired)· nominal 20-yr term from priority
Inventors:Teresa Lynn BurgessAngela CoxonLarry GreenKe Zhang
A61P 35/04A61P 35/00A61P 43/00A61P 35/02C07K 16/22A61K 2039/505C07K 2317/21C07K 2317/76C07K 2317/92A61K 45/06C07K 2317/56A61K 39/3955C07K 2317/73C07K 16/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of treating cancer in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:
 an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:24 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 25 from residue 20 to residue 141;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:26 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 27 from residue 20 to residue 137;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:28 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 29 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:30 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 from residue 20 to residue 148;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:32 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:34 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 35 from residue 20 to residue 144;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 from residue 20 to residue 142;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:40 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 41 from residue 20 to residue 140; and   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:42 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 43 from residue 20 to residue 139.   
     
     
         2 . The method of  claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 from residue 20 to residue 142. 
     
     
         3 . The method of  claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139. 
     
     
         4 . The method of  claim 1 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         5 . The method of  claim 1 , further comprising administering chemotherapy. 
     
     
         6 . The method of  claim 1 , further comprising administering radiation therapy. 
     
     
         7 . A method for treating cancer in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:
 an antibody comprising a light chain comprising SEQ ID NOs: 60, 70, and 80, and a heavy chain comprising SEQ ID NOs: 90, 100 and 110;   an antibody comprising a light chain comprising SEQ ID NOs: 61, 71, and 81, and a heavy chain comprising SEQ ID NOs: 91, 101, and 111;   an antibody comprising a light chain comprising SEQ ID NOs: 62, 72, and 82, and a heavy chain comprising SEQ ID NOs: 92, 102, and 112;   an antibody comprising a light chain comprising SEQ ID NOs: 63, 73, and 83, and a heavy chain comprising SEQ ID NOs: 93, 103, and 113;   an antibody comprising a light chain comprising SEQ ID NOs: 64, 74, and 84, and a heavy chain comprising SEQ ID NOs: 94, 104, and 114;   an antibody comprising a light chain comprising SEQ ID NOs: 65, 75, and 85, and a heavy chain comprising SEQ ID NOs: 95, 105, and 115;   an antibody comprising a light chain comprising SEQ ID NOs: 66, 76, and 86, and a heavy chain comprising SEQ ID NOs: 96, 106, and 116;   an antibody comprising a light chain comprising SEQ ID NOs: 67, 77, and 87, and a heavy chain comprising SEQ ID NOs: 97, 107, and 117;   an antibody comprising a light chain comprising SEQ ID NOs: 68, 78, and 88, and a heavy chain comprising SEQ ID NOs: 98, 108, and 118; and   an antibody comprising a light chain comprising SEQ ID NOs: 69, 79, and 89, and a heavy chain comprising SEQ ID NOs: 99, 109, and 119.   
     
     
         8 . The method of  claim 7 , wherein the antibody comprises a light chain comprising SEQ ID NOs: 66, 76, and 86, and a heavy chain comprising SEQ ID NOs: 96, 106, and 116. 
     
     
         9 . The method of  claim 7 , wherein the antibody comprises a light chain comprising SEQ ID NOs: 67, 77, and 87, and a heavy chain comprising SEQ ID NOs: 97, 107, and 117. 
     
     
         10 . The method of  claim 7 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         11 . The method of  claim 7 , further comprising administering chemotherapy. 
     
     
         12 . The method of  claim 7 , further comprising administering radiation therapy. 
     
     
         13 . A method for treating cancer in a patient, the method comprising administering a fully human antibody that binds human hepatocyte growth factor (HGF) comprising a light chain and a heavy chain, wherein the light chain comprises SEQ ID NOs: 67, 77, and 87 and the heavy chain comprises SEQ ID NOs: 97, 107, and 117. 
     
     
         14 . The method of  claim 13 , wherein the light chain further comprises the amino acid sequence of SEQ ID NO: 44 and the heavy chain further comprises the amino acid sequence of SEQ ID NO: 46. 
     
     
         15 . The method of  claim 13 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         16 . The method of  claim 13 , further comprising administering chemotherapy. 
     
     
         17 . The method of  claim 13 , further comprising administering radiation therapy. 
     
     
         18 . A method for treating cancer in a patient, the method comprising administering a fully human antibody that binds human hepatocyte growth factor (HGF) comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 38 from residue 21 to residue 128 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139. 
     
     
         19 . The method of  claim 18 , wherein the light chain further comprises the amino acid sequence of SEQ ID NO: 44 and the heavy chain further comprises the amino acid sequence of SEQ ID NO: 46. 
     
     
         20 . The method of  claim 18 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         21 . The method of  claim 18 , further comprising administering chemotherapy. 
     
     
         22 . The method of  claim 18 , further comprising administering radiation therapy. 
     
     
         23 . A method of treating cancer in a cancer patient, the method comprising administering an antibody which is capable of binding at least one amino acid sequence consisting of SEQ ID NO: 164 or SEQ ID NO: 165, wherein the antibody is humanized or fully human. 
     
     
         24 . The method of  claim 23 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         25 . The method of  claim 23 , further comprising administering chemotherapy. 
     
     
         26 . The method of  claim 23 , further comprising administering radiation therapy. 
     
     
         27 . A method of treating a solid tumor in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:
 an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:24 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 25 from residue 20 to residue 141;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:26 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 27 from residue 20 to residue 137;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:28 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 29 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:30 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 from residue 20 to residue 148;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:32 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:34 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 35 from residue 20 to residue 144;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 from residue 20 to residue 142;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139;   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:40 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 41 from residue 20 to residue 140; and   an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:42 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 43 from residue 20 to residue 139.   
     
     
         28 . The method of  claim 27 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 from residue 20 to residue 142. 
     
     
         29 . The method of  claim 27 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139. 
     
     
         30 . The method of  claim 27 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         31 . The method of  claim 27 , further comprising administering chemotherapy. 
     
     
         32 . The method of  claim 27 , further comprising administering radiation therapy. 
     
     
         33 . A method for treating a solid tumor in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:
 an antibody comprising a light chain comprising SEQ ID NOs: 60, 70, and 80, and a heavy chain comprising SEQ ID NOs: 90, 100 and 110;   an antibody comprising a light chain comprising SEQ ID NOs: 61, 71, and 81, and a heavy chain comprising SEQ ID NOs: 91, 101, and 111;   an antibody comprising a light chain comprising SEQ ID NOs: 62, 72, and 82, and a heavy chain comprising SEQ ID NOs: 92, 102, and 112;   an antibody comprising a light chain comprising SEQ ID NOs: 63, 73, and 83, and a heavy chain comprising SEQ ID NOs: 93, 103, and 113;   an antibody comprising a light chain comprising SEQ ID NOs: 64, 74, and 84, and a heavy chain comprising SEQ ID NOs: 94, 104, and 114;   an antibody comprising a light chain comprising SEQ ID NOs: 65, 75, and 85, and a heavy chain comprising SEQ ID NOs: 95, 105, and 115;   an antibody comprising a light chain comprising SEQ ID NOs: 66, 76, and 86, and a heavy chain comprising SEQ ID NOs: 96, 106, and 116;   an antibody comprising a light chain comprising SEQ ID NOs: 67, 77, and 87, and a heavy chain comprising SEQ ID NOs: 97, 107, and 117;   an antibody comprising a light chain comprising SEQ ID NOs: 68, 78, and 88, and a heavy chain comprising SEQ ID NOs: 98, 108, and 118; and   an antibody comprising a light chain comprising SEQ ID NOs: 69, 79, and 89, and a heavy chain comprising SEQ ID NOs: 99, 109, and 119.   
     
     
         34 . The method of  claim 33 , wherein the antibody comprises a light chain comprising SEQ ID NOs: 66, 76, and 86, and a heavy chain comprising SEQ ID NOs: 96, 106, and 116. 
     
     
         35 . The method of  claim 33 , wherein the antibody comprises a light chain comprising SEQ ID NOs: 67, 77, and 87, and a heavy chain comprising SEQ ID NOs: 97, 107, and 117. 
     
     
         36 . The method of  claim 33 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         37 . The method of  claim 33 , further comprising administering chemotherapy. 
     
     
         38 . The method of  claim 33 , further comprising administering radiation therapy. 
     
     
         39 . A method for treating a solid tumor in a patient, the method comprising administering a fully human antibody that binds human hepatocyte growth factor (HGF) comprising a light chain and a heavy chain, wherein the light chain comprises SEQ ID NOs: 67, 77, and 87 and the heavy chain comprises SEQ ID NOs: 97, 107, and 117. 
     
     
         40 . The method of  claim 39 , wherein the light chain further comprises the amino acid sequence of SEQ ID NO: 44 and the heavy chain further comprises the amino acid sequence of SEQ ID NO: 46. 
     
     
         41 . The method of  claim 39 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         42 . The method of  claim 39 , further comprising administering chemotherapy. 
     
     
         43 . The method of  claim 39 , further comprising administering radiation therapy. 
     
     
         44 . A method for treating a solid tumor in a patient, the method comprising administering a fully human antibody that binds human hepatocyte growth factor (HGF) comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 38 from residue 21 to residue 128 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 39 from residue 20 to residue 139. 
     
     
         45 . The method of  claim 44 , wherein the light chain further comprises the amino acid sequence of SEQ ID NO: 44 and the heavy chain further comprises the amino acid sequence of SEQ ID NO: 46. 
     
     
         46 . The method of  claim 44 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human HGF. 
     
     
         47 . The method of  claim 44 , further comprising administering chemotherapy. 
     
     
         48 . The method of  claim 44 , further comprising administering radiation therapy. 
     
     
         49 . A method of treating cancer in a cancer patient, the method comprising administering an antibody which is capable of binding at least one amino acid sequence consisting of SEQ ID NO: 164 or SEQ ID NO: 165, wherein the antibody is humanized or fully human. 
     
     
         50 . The method of  claim 49 , wherein the antibody is an immunologically functional immunoglobulin fragment that binds human hepatocyte growth factor. 
     
     
         51 . The method of  claim 49 , further comprising administering chemotherapy. 
     
     
         52 . The method of  claim 49 , further comprising administering radiation therapy.

Join the waitlist — get patent alerts

Track US2014154243A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.